These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35299139)

  • 21. Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review.
    Asian Network of Early Psychosis Writing Group
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):737-758. PubMed ID: 35451023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery.
    Chan SKW; Hui CLM; Chang WC; Lee EHM; Chen EYH
    Schizophr Res; 2019 Feb; 204():65-71. PubMed ID: 30126816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT.
    Morrison AP; Pyle M; Byrne R; Broome M; Freeman D; Johns L; James A; Husain N; Whale R; MacLennan G; Norrie J; Hudson J; Peters S; Davies L; Bowe S; Smith J; Shiers D; Joyce E; Jones W; Hollis C; Maughan D
    Health Technol Assess; 2021 Jan; 25(4):1-124. PubMed ID: 33496261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.
    Taipale H; Schneider-Thoma J; Pinzón-Espinosa J; Radua J; Efthimiou O; Vinkers CH; Mittendorfer-Rutz E; Cardoner N; Pintor L; Tanskanen A; Tomlinson A; Fusar-Poli P; Cipriani A; Vieta E; Leucht S; Tiihonen J; Luykx JJ
    JAMA Psychiatry; 2022 Mar; 79(3):210-218. PubMed ID: 35080618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
    Foster A; Buckley P; Lauriello J; Looney S; Schooler N
    J Clin Psychopharmacol; 2017 Oct; 37(5):595-599. PubMed ID: 28806390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome study of first-episode psychosis. I: Relapse rates after 1 year.
    Rabiner CJ; Wegner JT; Kane JM
    Am J Psychiatry; 1986 Sep; 143(9):1155-8. PubMed ID: 2875663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting first-episode psychosis patients who will never relapse over 10 years.
    Hui CL; Honer WG; Lee EH; Chang WC; Chan SK; Chen ES; Pang EP; Lui SS; Chung DW; Yeung WS; Ng RM; Lo WT; Jones PB; Sham P; Chen EY
    Psychol Med; 2019 Oct; 49(13):2206-2214. PubMed ID: 30375301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders.
    Chan SKW; Chan SWY; Pang HH; Yan KK; Hui CLM; Chang WC; Lee EHM; Chen EYH
    JAMA Psychiatry; 2018 May; 75(5):458-464. PubMed ID: 29617517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review.
    Zipursky RB; Menezes NM; Streiner DL
    Schizophr Res; 2014 Feb; 152(2-3):408-14. PubMed ID: 23972821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
    Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
    Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia.
    Chang WC; Lau ES; Chiu SS; Hui CL; Chan SK; Lee EH; Chen EY
    J Affect Disord; 2016 Aug; 200():1-5. PubMed ID: 27107261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Specialised first-episode psychosis services: a systematic review of the literature].
    Skalli L; Nicole L
    Encephale; 2011 May; 37 Suppl 1():S66-76. PubMed ID: 21600336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prescription practices of antipsychotic medication in early psychosis: a two-year follow-up survey of subjects admitted in two psychiatric hospitals of South-Western France].
    Grolleau A; Cougnard A; Parrot M; Kalmi E; Desage A; Misdrahi D; Brun-Rousseau H; Verdoux H
    Encephale; 2007; 33(3 Pt 1):326-31. PubMed ID: 17675930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.